CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Bought by Deutsche Bank AG

Deutsche Bank AG boosted its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 65.0% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 8,133 shares of the company’s stock after buying an additional 3,205 shares during the quarter. Deutsche Bank AG’s holdings in CRISPR Therapeutics were worth $320,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in CRSP. KBC Group NV grew its position in CRISPR Therapeutics by 2,047.4% during the fourth quarter. KBC Group NV now owns 60,514 shares of the company’s stock valued at $2,382,000 after buying an additional 57,696 shares during the period. Perigon Wealth Management LLC lifted its holdings in CRISPR Therapeutics by 11.4% during the fourth quarter. Perigon Wealth Management LLC now owns 16,757 shares of the company’s stock valued at $675,000 after purchasing an additional 1,717 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in CRISPR Therapeutics by 10.5% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 18,098 shares of the company’s stock valued at $712,000 after purchasing an additional 1,717 shares in the last quarter. Spire Wealth Management lifted its holdings in CRISPR Therapeutics by 303.7% during the fourth quarter. Spire Wealth Management now owns 1,970 shares of the company’s stock valued at $78,000 after purchasing an additional 1,482 shares in the last quarter. Finally, Western Pacific Wealth Management LP lifted its holdings in CRISPR Therapeutics by 100.0% during the fourth quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company’s stock valued at $39,000 after purchasing an additional 500 shares in the last quarter. Institutional investors and hedge funds own 69.20% of the company’s stock.

Insiders Place Their Bets

In other CRISPR Therapeutics news, insider Naimish Patel sold 3,932 shares of CRISPR Therapeutics stock in a transaction dated Thursday, May 29th. The shares were sold at an average price of $35.94, for a total transaction of $141,316.08. Following the completion of the sale, the insider now directly owns 6,068 shares in the company, valued at $218,083.92. This trade represents a 39.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, General Counsel James R. Kasinger sold 2,850 shares of CRISPR Therapeutics stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total transaction of $120,897.00. Following the sale, the general counsel now owns 77,530 shares of the company’s stock, valued at approximately $3,288,822.60. This represents a 3.55% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 17,953 shares of company stock valued at $736,087 over the last ninety days. Company insiders own 4.10% of the company’s stock.

Analyst Ratings Changes

Several research firms have issued reports on CRSP. Chardan Capital decreased their price objective on shares of CRISPR Therapeutics from $84.00 to $82.00 and set a “buy” rating on the stock in a report on Wednesday, May 7th. Citigroup decreased their price objective on shares of CRISPR Therapeutics from $89.00 to $82.00 and set a “buy” rating on the stock in a report on Tuesday, February 18th. Royal Bank of Canada decreased their price objective on shares of CRISPR Therapeutics from $53.00 to $48.00 and set a “sector perform” rating on the stock in a report on Wednesday, February 12th. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of CRISPR Therapeutics in a report on Wednesday, February 19th. Finally, Evercore ISI raised shares of CRISPR Therapeutics from an “in-line” rating to an “outperform” rating and raised their price target for the stock from $60.00 to $99.00 in a research note on Friday, February 14th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and ten have given a buy rating to the company. According to MarketBeat.com, CRISPR Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $71.75.

CRISPR Therapeutics Price Performance

Shares of CRSP stock opened at $36.04 on Friday. The firm’s 50-day moving average is $36.59 and its two-hundred day moving average is $41.43. CRISPR Therapeutics AG has a 12 month low of $30.04 and a 12 month high of $67.88. The company has a market capitalization of $3.11 billion, a PE ratio of -8.25 and a beta of 1.88.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its earnings results on Tuesday, May 6th. The company reported ($1.58) EPS for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.31). CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. During the same quarter in the previous year, the company earned ($1.43) EPS. CRISPR Therapeutics’s revenue was up 71.6% compared to the same quarter last year. Sell-side analysts forecast that CRISPR Therapeutics AG will post -5.16 EPS for the current year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.